Biofrontera Inc.
BFRI • NASDAQ
Biofrontera Inc. is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Hermann Luebbert, with a market cap of $9.5M.
CEOHermann Luebbert
Market Cap$9.5M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees85.0
Websitebiofrontera-us.com
Next Earnings
Upcoming earnings announcement for Biofrontera Inc.
Date
Thursday, May 14, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.10
Revenue Estimate
$10.0M
Earnings History
Past 12 earnings reports for Biofrontera Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | $0.48Est: $0.18 | +166.7% | $17.1MEst: $16.6M | +3.0% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.62Est: -$0.58 | -6.9% | $7.0MEst: $7.0M | -0.2% | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.57Est: -$0.41 | -39.0% | $9.0MEst: $8.3M | +9.3% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.47Est: -$0.29 | -62.1% | $8.6MEst: $10.6M | -18.6% | 10-Q |
| Mar 21, 2025 | Q4 2024 | -$0.19 | — | $12.6M | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.98Est: -$0.83 | -18.1% | $9.0MEst: $10.0M | -10.0% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.05Est: -$0.77 | +93.5% | $7.9MEst: $8.2M | -3.9% | 10-Q |
| May 15, 2024 | Q1 2024 | -$2.88Est: -$1.17 | -146.2% | $7.9MEst: $10.9M | -27.1% | 10-Q |
| Mar 15, 2024 | Q4 2023 | $1.65Est: -$1.19 | +238.7% | $10.6MEst: $11.5M | -8.0% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$4.64Est: -$4.26 | -8.9% | $8.9MEst: $7.0M | +26.5% | — |
| Aug 11, 2023 | Q2 2023 | -$7.23Est: -$5.14 | -40.7% | $5.8MEst: $5.9M | -0.2% | 10-Q |
| May 12, 2023 | Q1 2023 | -$5.60Est: -$3.80 | -47.4% | $8.7MEst: $9.2M | -4.6% | — |